Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i)

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 4, 2000, Pages 380-386

  Jackson, Brian ^a   Gee, Andrew N ^a   Guyon Gellin, Yves ^b   Niesor, Eric ^b   Bentzen, Craíg L ^b   Kerns, William D ^a   Suckling, Keith E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Symphar Research Laboratories   (Switzerland)

Author keywords

CAS 126411 13 0; SR 9223i, antiatherosclerotic and hypocholesterolaemic effects, dog, hamster, monkey, mouse, rabbit; Tetra iso propyl 2 (3,5 di tert butyl 4 hydroxyphenyl)ethyl 1,1 diphosphonate

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; PHOSPHONIC ACID DERIVATIVE; SR 9223I; TETRAISOPROPYL 2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL)ETHYL 1,1 DIPHOSPHONATE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; HAMSTER; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; MALE; MONKEY; MOUSE; NONHUMAN; RABBIT;

EID: 0033997606     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300217     Document Type: Article

References (20)

1. [1] Kjekshus, J., Pedersen, T. R., Reducing the risk of coronary events - evidence from the Scandinavian Simvastatin Survival Study (4s). Am. J. Cardiol. 76, 64C (1995)
2. [2] Shepherd, J., The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am. J. Cardiol. 76, 113C (1995)
3. [3] Penn, M. S., Chisolm, G. M., Oxidized lipoproteins, altered cell-function and atherosclerosis. Atherosclerosis 108, S 21 (1994)
4. [4] Jialal, I., Fuller, C. J., Effect of vitamin-E, vitamin-C and beta-carotene on LDL oxidation and atherosclerosis. Can. J. Cardiol. 11 (Suppl. G), G 97 (1995)
5. [5] Sliskovic, D. R., White, A. D., Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 12, 194 (1991)
6. [6] Billheimer, J. T., Gillies, P. J., Intracellular cholesterol esterification, in: Advances in cholesterol research, M. Esfahani, J. B. Swaney (eds.), pp. 7-45, The Telford Press, New Jersey (1990)
7. [7] Suckling, K. E., Kerns, W. D., Jackson, B. et al., SK& F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, lowers plasma cholesterol in normocholesterolemic animals. Atherosclerosis 109, 166 (1994)
8. [8] Berkhout, T., Simon, H., Niesor, E et al., SK&F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, suppresses HMG-CoA reductase and induces LDL receptor activity by a novel mechanism. Atherosclerosis 109, 167 (1994)
9. [9] Niesor, E., Meachler, P., Lolli, D. et al., SK&F 99085/ SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, inhibits ACAT and lipoprotein oxidation. Atherosclerosis 109, 167 (1994)
10. [10] Bentzen, C. L., Guyon, Y., Latin, P. et al., SK&F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, decreases cholesterol absorption and tissue deposition in rabbits by inhibiting cholesterol esterification (ACAT). Atherosclerosis 109, 167 (1994)
11. [11] Folch, J., Lees, M., Sloan-Stanley, G. H., A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 266, 497 (1956)
12. [12] Becker, R. H. A., Ace-inhibition and experimental atherosclerosis. Zeitschrift Für Kardiologie 83, 15 (1994)
13. [13] Bocan, T. M. A., Mazur, M. J., Mueller, S. B. et al., Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 111, 127 (1994)
14. [14] Berkhout, T. A., Simon, H. M., Patel, D. D. et al., The novel cholesterol-lowering drug SR-12813 inhibits cholesterol-synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 271, 14376 (1996)
15. [15] Haugen, R., Norum, K. R., Coenzyme A-dependent esterification of cholesterol in rat intestinal mucosa. Scand. J. Gastroent. 11, 615 (1976)
16. [16] Field, F. J., Cooper, A. D., Erickson, S. K., Regulation of rabbit intestinal acyl coenzyme a-cholesterol acyltransferase in vivo and in vitro. Gastroenterol. 83, 873 (1982)
17. [17] Zhou, X. H., Paulsson, G., Stemme, S. et al., Hypercholesterolemia is associated with a T-helper (Th) 1/Th2 switch of the autoimmune-response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101, 1717 (1998)
18. [18] Steinberg, D., Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272, 20963 (1997)
19. [19] Ma, X. L., Yue, T. L., Lopez, B. L. et al., Carvedilol, a new beta-adrenoceptor blocker and free-radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J. Pharmacol. Exp. Ther. 277, 128 (1996)
20. [20] Fennessy, P. A., Campbell, J. H., Mendelsohn, F. A. O. et al., Angiotensin-converting enzyme-inhibitors and atherosclerosis: relevance of animal models to human disease. Clin. Exp. Pharmacol. Phys. 23, S 30 (1996)